Stem cells and diversity

Leukemia

Volumn 17, Issue 6, 2003, Pages 1042-1048

  McCulloch, E A ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; RETINOIC ACID RECEPTOR ALPHA;

ACUTE MYELOBLASTIC LEUKEMIA; CELL COMPOSITION; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL RENEWAL; CHROMOSOME 22; CHROMOSOME 9; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; CLONOGENIC ASSAY; COLONY FORMING UNIT S; GENE CONTROL; GENETIC CODE; GENOTYPE; HUMAN; IONIZING RADIATION; MOLECULAR CLONING; MOUSE; NONHUMAN; NOTE; PHILADELPHIA 1 CHROMOSOME; PLASTICITY; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; TREATMENT OUTCOME;

EID: 0038344690     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402948     Document Type: Note

References (98)

1. Till JE, McCulloch EA. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res 1961; 14: 213-222.
2. Becker AJ, McCulloch EA, Till JE. Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature 1963; 197: 452.
3. Siminovitch L, McCulloch EA, Till JE. The distribution of colony-forming cells among spleen colonies. J Cell Comp Physiol 1963; 62: 327-336.
4. Arley N. Stochastic processes and their Application to the Theory of Cosmic Radiation. New York Wiley, 1943.
5. Feller W. An Introduction to Probability Theory and its Applications. New York: Wiley, 1957.
6. Till JE, McCulloch EA, Siminovitch L. A stochastic model of stem cell proliferation, based on the growth of spleen colony forming cells. Proc Natl Acad Sci (USA) 1964; 51: 29-36.
7. Cotter TG, Lennon SV, Glynn JG, Martin SJ. Cell death via apoptosis and its relationship to growth. Development and differentiation of both tumor and normal cells. Anticancer Res 1990; 10: 1153-1160.
8. Russell ES. Hereditary anemias of the mouse. A review for geneticists. Adv Genet 1979; 20: 357.
9. v. Science 1964; 144: 844-846.
10. d. Blood 1965; 26: 399-410.
11. Lemischka IR, Raulet D, Mulligan RC. Developmental potential and dynamic behaviour of hematopoietic stem cells. Cell 1986; 45: 917-927.
12. Spangrude GJ, Heimfeld S, Weissman IL. Purification and characterization of mouse hematopoietic stem cells. Science 1988; 241: 58-62.
13. Muller-Sieburg CE, Townsend K, Weissman IL, Rennick D. Proliferation and differentiation of highly enriched mouse hematopoietic stem cells and progenitor cells in response to defined growth factors. J Exper Med 1988; 167: 1825-1840.
14. Spangrude GJ, Smith L, Uchida N, Ikuta K, Heimfeld S, Friedman J et al. Mouse hematopoietic stem cells. Blood 1991; 78: 1395-1402.
15. Jones RI, Wagner JE, Celano P, Zicha MS, Sharkis SJ. Separation of of pluripotent haematopoietic stem cells from spleen colony-forming cells. Nature 1990; 347: 188-189.
16. Bradley TR, Metcalf D. The growth of mouse bone marrow cells in vitro. Aust J Exp Biol Med Sci 1966; 44: 287-299.
17. Pluznik DH, Sachs L. The cloning of normal 'mast' cells in tissue culture. J Cell Comp Physiol 1966; 66: 319-324.
18. Metcalf D. Summon up the blood. In: Dogged Pursuit of Blood Cell Regulators. Miamisburg: Alphamed Press, 2000.
19. Stephenson JR, Axelrad AA, McLeod DC, Shreeve M. Induction of colonies of hemoglobin-synthesizing cells by erythropoietin in vitro. Proc Natl Acad Sci (USA) 1971; 68:1542-1546.
20. McLeod DL, Shreeve MM, Axelrad AA. Improved plasma culture system for production of erythrocytic colonies in vitro. Quantitative assay method for CFU-E. Blood 1974; 44: 517-534.
21. Heath DS, Axelrad AA, Mcleod DL. Separation of erythropoietin-responsive progenitors BFU-E, CFU-E in mouse bone marrow by unit gravity sedimentation. Blood 1976; 47: 777-792.
22. Wendling F, Maraskovsky E, Debili N, Teepe M, Methia N, Breton-Gorius J et al. c-Mpl ligand is a humoral regulator of megakaryoytopoiesis. Nature 1994; 369: 571-574.
23. Sauvage FJD, Spencer SD, Gurney AL, Darbonne WC, Wong SC, Oles Jr KL et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994; 369: 533-538.
24. Fibach E, Gerassi E, Sachs L. Induction of colony-formation in vitro by human lymphocytes. Nature 1976; 259: 127.
25. Izaguirre CA, Minden MD, Howatson AF, McCulloch EA. Colony formation by normal and malignant B lymphocytes. Br J Cancer 1980; 42: 430-437.
26. Goldwasser E. Erythropoietin and the differentiation of red blood cells. Fed Proc 1976; 34: 2285-2292.
27. Goldwasser E. Erythropoietin and its mode of action. Blood Cells 1984; 10: 147-162.
28. Jacobs K, Rudersdorph R, Kaufman RJ, Seehra J, Hewick R, Kawakita M et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 1985; 313: 806-810.
29. Lin FK, Lin CH, Smalling R, Chen KK, Martin F, Stabinsky Z et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci (USA) 1985; 82: 7580.
30. Fung MC, Hapel AJ, Ymer S, Cohen DR, Johnson RM, Campbell HD et al. Molecular cloning of cDNA for murine interleukin-3. Nature 1984; 307: 233-237.
31. Gough NM, Gough J, Metcalf D, Kelso A, Grail D, Nicola N et al. Molecular cloning of cDNA encoding a murine hematopoietic growth regulator, granulocyte-macrophage colony stimulating factor. Nature 1984; 309: 763-767.
32. Metcalf D. Control of granulocytes and macrophages: molecular, cellular and clinical aspects. Science 1991; 254: 529-533.
33. Nagata S, Asano S, Yamazaki T, Hirata Y, Oheda M, Ono M. Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor. Nature 1986; 319: 415-417.
34. Nagata S, Tsuchiya T, Asano S, Yamamoto O, Hirata Y, Kubota N et al. The chromosome gene structure and two mRNAs for human granulocyte colony-stimulating factor. EMBO J 1986; 5: 575-581.
35. Kaushansky K, Holly RD, Lin N, Forstrom JW, Oort PJ, Roth GJ et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994; 369: 568-571.
36. Lok SL, Kaushansky K, Holly RD, Kuijper JL, Lofton-Day CE, Oort PJ et al. Cloning and expression of the murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994; 369: 565-568.
37. Kaushansky K. Thrombopoietin; the primary regulator of platelet production. Blood 1995; 86: 419-431.
38. Qiu F, Ray P, Brown K, Barker PE, Jhanwar S, Ruddle FH et al. Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase family - oncogenic activation of v-kit involves deletion of extracellular domain and C terminus. EMBO J 1988; 7: 1003-1011.
39. Chabot B, Stephenson DA, Chapman VM, Besner P, Bernstein A. The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 1988; 335: 88-89.
40. Nocka K, Majumder S, Chabot B, Ray P, Cervone M, Bernstein A et al. Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice-evidence for an impaired c-kit kinase in mutant mice. Genes and Develop 1989; 3: 816-826.
41. Ashman LK, Cambareri AC, To LB, Levinsky RJ, Juttner CA. Expression of the YB5.B8 antigen (c-kit proto-oncogene product) in normal human bone marrow. Blood 1991; 78: 30-37.
42. c-kit)is a human bone marrow surface antigen of hemopoietic precursor cells that is expressed on a subset of acute non-lymphoblastic leukemic cells. Leukemia 1991; 10: 854-860.
43. Witte ON. Steel locus defines new multipotent growth factor. Cell 1990; 63: 5-6.
44. Anderson DM, Lyman SD, Wignall JM, Eisenman J, March CJ, Gimpel SD et al. Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound, soluble forms. Cell 1990; 63: 235-243.
45. Copeland MG, Gilbert DJ, Donovan PJ, Jenkins NA, Cosman D, Anderson D et al. Mast cell growth factor maps near the steel locus on mouse chromosome 10 and is deleted in a number of steel alleles. Cell 1990; 63: 175-183.
46. Huang E, Nocka K, Chu T-Y, Buck J, Lanhm H-W, Wellner D et al. The hematopoietic growth factor KL is encoded by the SI locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell 1990; 63: 235-243.
47. Williams DE, Eisenman J, Baird A, Ness KV, Park LS, Mochizuki DY et al. Identification of a ligand for the c-kit proto-oncogene. Cell 1990; 63: 167-174.
48. Kanakura Y, Druker B, Cannistra. SA, Furukawa Y, Torimoto Y, Griffin JD. Signal transduction of the human granulocyte-macrophage colony-stimulating factor and interleukin-3 receptors involves tyrosine phosphorylation of a common set of cytoplasmic proteins. Blood 1990; 76: 706-715.
49. Majerus PW, Connolly TM, Deckmyn H, Ross TS, Bross TE, Ishii H et al. The metabolism of phosphoinositide-derived messenger molecules. Science 1987; 234: 1519-1526.
50. Freissmuth M, Casey PJ, Gilman AG. G proteins control diverse pathways of transmembrane signaling. FASEB J 1989; 3: 2125-2131.
51. Darell Jr, Kerr IM, Stark GR. Jak-stat pathways and transcriptional activation in response to IFNs and other extracellular signalling proteins. Science 1994; 264: 1415-1421.
52. Chinnaiyan AM, O'Rourke K, Lane BR, Dixit VM. Interaction of CED-4 with CED-3 and CED-9: a molecular framework for cell death. Science 1997; 275: 1122-1126.
53. Castedo M, Hirsch T, Susin SA, Zamami M, Marchetti P, Macho A et al. Sequential acquisition of mitochondrial and plasma membrane alterations during lymphocyte apoptosis. J Immunol 1996; 20: 512-521.
54. Hockenbery D, Nunez G, Millman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334.
55. Hockenbery DM, Oltvai ZN, Yin X-M, Milliman CL, Korsmeyer SJ. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 1993; 75: 241-251.
56. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. Bad, a heterodimeric partner of Bcl-xl and bcl-2, displaces bax and promotes cell death. Cell 1995; 80: 285-291.
57. Korsmeyer S. Regulators of cell death. Trends Genet 1995; 11: 101-105.
58. Nowell PC, Hungerford DA. Chromosome studies in human leukemia. II. Chronic granulocytic leukemia. J Natl Cancer Inst 1961; 27: 1013-1035.
59. Fialkow PJ, Gartler SM, Yoshida A. Clonal origin of chronic myelocytic leukemia in man. Proc Natl Acad Sci (USA) 1967; 58: 1468-1471.
60. Fialkow PJ, Singer JW, Adamson JW, Vaidya K, Dow LW, Ochs J et al. Acute nonlymphocytic leukemia: heterogeneity of stem cell origin. Blood 1981; 57: 1068-1073.
61. Fialkow PJ, Janssen JWG, Bartram CR. Prospective: clonal remissions in acute nonlymphocytic leukemia: evidence for a multistep pathogenesis of the malignancy. Blood 1991; 77: 1415-1417.
62. Jacobson RJ, Salo A, Fialkow PJ. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood 1978; 51: 189-194.
63. Adamson JW, Fialkow PJ, Murphy S, Prchal JE, Steinmann L. Polycythemia vera: stem cell and probable clonal origin of the disease. New Engl J Med 1976; 295: 913-916.
64. McCulloch EA, Till JE. Stem cells in normal early haemopoiesis and certain clonal haemopathies. in: Recent Advances in Haematology. Churchill Livingston, London, New York, 1977, pp 85-110.
65. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and giemsa staining. Nature 1973; 243: 290-293.
66. Groffen J, Stephenson JR, Heistrkamp N, de Klein A, Bartram CR, Grosveld G. Philadephia chromosome breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984; 36: 93-99.
67. Gishizky M, Witte ON. Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro. Science 1992; 256: 836-839.
68. Rowley JD, Golomb HM, Dougherty C. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukemia. Lancet 1977; (i): 549.
69. de The H, Chomienne C, Lanotte M, Degos L, Dejean D. The t(15:17) translocation of acute promyelocytic leukemia fuses the retinoic acid receptor a gene to a novel transcribed locus. Nature 1990; 347: 558-561.
70. Chomienne C, Ballerini P, Balitrand N, Daniel MT, Fenaux P, Castaigne S, Degos L. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. II. In vitro studies: structure-funcion relationship. Blood 1990; 76: 1710-1717.
71. Estey EH, Keating MJ, Dixon DO, Trujillo JM, McCredie KB, Freireich EJ. Karyotype is prognostically more important than the FAB system distinction between myelodysplastic syndrome and acute myelogenous leukemia. Hematol Pathol 1987; 1: 203-208.
72. Buick RN, Till JE, McCulloch EA. Colony assay for proliferative blast cells circulating in myeloblastic leukaemia. Lancet 1977; 1: 862-863.
73. Dicke KA, Spitzer G, Ahearn MJ. Colony-formation in vitro in acute myelogenous leukemia with phytohaemagglutinin as stimulating factor. Nature 1976; 259: 129-130.
74. Lowenberg B, Swart K, Hagemeijer A. PHA-induced colony-formation in acute nonlymphocytic and chronic myeloid leukemia. Leukemia Res 1980; 4: 143-149.
75. Hoang T, Nara N, Wong G, Clark S, Minden MD, McCulloch EA. The effects of recombinant GM-CSF on the blast cells of acute myeloblastic leukemia. Blood 1986; 67: 313-316.
76. Tanikawa S, Nakao I, Tsuneoka K, Nara N. Effects of recombinant granuocyte colony-stimulating factor (G-CSF) and recombinant granulocyte-macrophage stimulating factor (GM-CSF) on acute radiation hematopoietic injury in mice. Exp Hematol 1989; 17: 883-888.
77. Miyauchi J, Kelleher CA, Wong GG, Yang Y-C, Clark SC, Minkin S et al. The effects of combinations of the recombinant growth factors GM-CSF, G-CSF, IL-3 and CSF-1 on leukemic blast cells in suspension culture. Leukemia 1988; 2: 382-387.
78. Kelleher C, Miyauchi J, Wong G, Clark S, Minden MD, McCulloch EA. Synergism between recombinant growth factors, GM-CSF and G-CSF, acting on the blast cells of acute myeloblastic leukemia. Blood 1987; 69: 1498-1503.
79. Lowenberg B, van Putten WLJ, Touw IP, Delwel R, Santini V. Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. N Engl J Med 1993; 328: 614-619.
80. McCulloch EA, Minkin S, Curtis JE, Minden MD. Response of the blast stem cells of acute myelogenous leukemia to G-CSF, GM-CSF or the ligand for c-KIT, alone or in combination. Hematopathol Mol Hematol 1996; 10: 111-122.
81. Buick RN, Chang LJ-W, Messner HA, Curtis JE, McCulloch EA. Self renewal capacity of leukemic blast progenitor cells. Cancer Res 1981; 41: 4849-4852.
82. Delmer A, Marie J-P, Thevenin D, Cadiou M, Viguie F, Zittoun R. Multivariate analysis of prognostic factors in acute myeloid leukemia: value of clonogenic leukemic cell properties. J Clin Oncol 1989; 7: 738-746.
83. Nara N. Association between secondary colony-plating efficiency of blast progenitors and the remission induction outcome of acute myeloblastic leukemia patients. Acta Haematol (Japan) 1988; 51: 1624-1629.
84. Minkin S. A statistical model for in-vitro assessment of patient sensitivity to cytotoxic drugs. Biometrics 1991; 47: 1581-1591.
85. Minkin S, Chow A. Assessing sensitivity in suspension to cytosine arabinoside: Statistical analysis, associations with clinical outcome and experimental design. Statist Med 1995; 14: 1081-1095.
86. Meng-er H, Yu-chen Y, Shu-rong C, Jin-ren C, Jia-Xiang L, Lin Z et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567-572.
87. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, Degos L. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia I. Clinical results. Blood 1990; 76: 1704-1709.
88. Fenaux P, LeDeley MC, Castaigne S, Archambaud E, Chomienne C, Link H et al. Effect of all trans retinoic acid in newly diagnosed acute promyelocyctic leukemia. Results of a multicentre randomized trial. Blood 1993; 82: 3241-3249.
89. Druker BJ, Lydon MB. Lessons learned from the development of an abl tyrosine kinase inhibitor fror chronic myelogenous leukemia. J Clin Invest 2000; 105: 3-7.
90. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia. New Engl J Med 2001; 344: 1031-1037.
91. Peterson BE, Bowen WC, Patrene KD, Mars W, Sullivan AK, Murase N et al. Bone marrow as a potential source of hepatic oval cells. Science 1999; 284: 1168-1170.
92. Goodel MA, Jackson KA, Majka SM, Mi T, Wang H, Pocius J et al. Stem cell plasticity in muscle and bone marrow. Ann N Y Acad Sci 2001; 938: 208-218.
93. Jackson KA, Mi T, Goodel MA. Hematopoietic potential of stem cells isolated from murine skeletal muscle. Proc Natl Acad Sci USA 1999; 96: 14482-14486.
94. Ferrari G, Cusella-De Angelis G, Coleta M, Paolucci E, Stornaiuolo CB, Cossu G et al. Muscle regeneration by bone marrow-derived myogenic progenitors. Science 1998; 279: 1528-1530.
95. Bjornson CRR, Rietze RL, Reynolds BA, Magli MC, Vescovi AL. Turning brain into blood: a hematopoietic fate adopted by adult neural stem cells in vivo. Science 1999; 283: 534-536.
96. Brazelton TR, Rossi FMV, Kekshet GI, Blau HM. From marrow to brain: expression of neuronal phenotypes in adult mice. Science 2000; 290: 1775-1779.
97. Wulf GG, Jackson KA, Goodell MA. Somatic stem cell plasticity: current evidence and emerging concepts. Exp Hematol 2001; 29: 1361-1370.
98. Greco FA, Hainsworth JD. Cancer of unknown primary site. In: De Vita VTJ, Hellman S, Rosenberg SA (eds). Cancer: Principles and Practice of Oncology. Philadelphia, Baltimore, London, Hong Kong: Lippincott, Williams and Wilkins, 2001, pp. 2537-2560.